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BACKGROUND
ACE-I/ARBs are commonly prescribed medications for
hypertension, congestive heart failure, diabetes, and
renal disease, and providers across specialties often see
patients taking an ACE-I/ARB; lisinopril holds a place as
the third most prescribed drug in the United States, with
87.4 million prescriptions written for in 2010.1 TMP-SMX
is a widely used antibiotic for both in- and outpatient
settings, good for bacterial infections ranging from
uncomplicated urinary tract infections to methicillin-
resistant Staphylococcus aureus infections to respiratory
tract infections. It is a staple medication on the WHO
Model List of Essential Medicines.2
While both drugs are commonly prescribed, the safety of
coadministration has not been fully evaluated. Both
drugs are capable of increasing serum potassium and
causing hyperkalemia, a metabolic abnormality that can
cause weakness, cardiac arrhythmias, and death.
METHODS
HYPERKALEMIA
Hyperkalemia can be a serious metabolic abnormality,
manifesting with symptoms including weakness,
paralysis, metabolic acidosis, arrhythmias, sudden cardiac
arrest, and death.
ACE-I/ARBs have the potential to cause hyperkalemia due
to blockade of the renin-angiotensin-aldosterone
pathway. Aldosterone, the terminal product of this
pathway, upregulates the Na+/K+ ATPase pumps found in
the distal convoluted tubule of the kidney. This leads to
an increase in serum sodium and a decrease in serum
potassium. Free water follows the retained sodium,
increasing intravascular volume and blood pressure. ACE-
I/ARBs decrease blood pressure by stopping the
production of aldosterone, leading to increased urine
output, decreased serum sodium, increased serum
potassium, and decreased blood pressure.3
The trimethoprim component of TMP-SMX increases
serum potassium through its similarities to amiloride, a
potassium-sparing diuretic. Instead of directly increasing
potassium reabsorption like renin-angiotensin-
aldosterone blockers, they indirectly increase serum
potassium by decreasing sodium reabsorption in the
distal convoluted tubule, leading to increased urine
sodium, increased urine, and decreased urinary
potassium. Trimethoprim may also have an effect on the
Na+/K+ ATPase pumps in the distal tubule.4,5
Ovid-Medline, Web of Science, Google Scholar, and Ovid
International Pharmaceutical Abstracts were searched
using the terms TMP-SMX and ACE inhibitor and ARB was
done. Eligibility criteria included studies in the English
language, studies that included concurrent use of TMP-
SMX and ACE inhibitors or ARBs, and studies focused on
on-label uses of TMP-SMX. Three articles met inclusion
criteria and were evaluated with GRADE criteria—one
retrospective cohort study6 from Ehime, Japan examining
hyperkalemia in patients on an ACE-I/ARB prescribed
low-dose TMP-SMX and two population-based, nested
case-control studies7,8 out of Ontario, Canada examining
the risk of hyperkalemia-associated hospitalization or
sudden death associated with concomitant TMP-SMX and
ACE-I/ARB use.
RESULTS
THE BOTTOM LINE
Providers should be aware that prescribing TMP-SMX to patients already taking
and ACE-inhibitor or ARB, especially elderly patients and those with renal
insufficiency, may lead to poor outcomes that include development of
hyperkalemia, hospitalization, and sudden death. When treating these
populations, clinicians should consider whether there is an alternative and equally
efficacious antibiotic; if one is not available, consideration to renal function and
potential metabolic monitoring should be given.
Future studies would benefit from continuing to utilize patient-centered
outcomes, creating a head-to-head comparison of TMP-SMX risk with and without
concomitant ACE-I/ARB use, eliminating possible confounding related to other
antibiotic use, and including younger patients.
GRADE characteristics of included studies
Study Design
Downgrade Criteria
Quality
Limitations Indirectness Inconsistency Imprecision
Publication 
bias
Higashioka 
et al6
Retrospective 
cohort Not serious Not serious Not serious Serious Unlikely
Very 
Low
Antoniou 
et al 7
Population 
based 
nested case-
control study Seriousb Not serious Not serious Not serious Unlikely
Very 
Low
Fralick
et al8
Population 
based 
nested case-
control study Serious Not serious Not serious Not serious Unlikely Very low
aVery wide CI, low precision of results
bConfounding variables present and case vs control groups not clearly equal
Summary of findings
Antibiotic Adjusted OR of 
developing  
hyperkalemia 
(95% CI)6
Adjusted OR of 
hospitalization with 
diagnosis of hyperkalemia at 
14 days post-antibiotic 
prescription (95% CI)7
Adjusted OR of sudden death at 
14 days post-antibiotic 
prescription (95% CI)8
Low-dose TMP-SMX 1.97 (.82-4.71) -- --
Low-dose TMP-SMX 
with renal 
insufficiency 
(eGFR < 
60mL/min/1.73m2)
3.96 (1.17-13.4) -- --
Amoxicillin (reference) --- 1.0 1.0
TMP-SMX, dose 
unknown
--- 6.7 (4.5-10.0) 1.54 (1.29-1.84)
Ciprofloxacin --- 1.4 (0.9-2.2) 1.18 (1.00-1.39)
Norfloxacin --- 0.8 (0.4-1.5) 0.83 (0.65-1.05)
Nitrofurantoin --- 1.1 (0.6-2.0) 1.03 (0.81-1.30)
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All three studies6,7,8 found an increased risk of ACE-I/ARB
patients prescribed TMP-SMX having an adverse outcome.
Higashioka et al found an increased risk for development of
hyperkalemia in patients who already had renal
insufficiency. Antoniou et al found an increased risk of
hospitalization with a diagnosis of hyperkalemia in elderly
patients. Fralick et al found an increased risk of sudden
death in elderly patients. Both Higashioka et al6 and
Antoniou et al7 showed a large magnitude of effect,
suggesting results are worth considering in clinical practice
even with study limitations. While Fralick et al11 may not
have shown as large an effect, the seriousness of the
outcome (sudden death) leads the prudent clinician to
consider their results.
The GRADE quality of evidence for all three of these
retrospective cohort studies is very low. Although they
have large and robust sample sizes, Fralick et al8 and
Antoniou et al7 draw from the same population database,
leading to the possibility of some selection bias. While
Higashioka et al draws from a different population, the
population size is significantly smaller and comes from a
single medical center in Japan. Higashioka et al6 was the
only study to include patients younger than 66 years;
despite this, average age was still 66 years, leaving
applicability to younger patients unknown.
Other limitations included lack of patient-centered
outcomes, possible confounding due to antibiotic usage,
lack of information on TMP-SMX and ACE-I/ARB dosing.
Case cohorts also had a higher likelihood of having a history
of hyperkalemia or residing in a long-term care facility
(Antoniou et al) or having renal disease, heart failure, or loop
diuretic use (Fralick et al).6,7,8,9,10,11
Further research is needed to fully understand that potential
risks of TMP-SMX use in patients already prescribed an ACE-
I/ARB. A direct comparison of patients with/without ACE-
I/ARB prescription who are given TMP-SMX along with dose-
dependent results for both ACE-I/ARB and TMP-SMX would
provide valuable information. Additionally, reviewed studies
are fairly limited to elderly patients, and the impact of
concomitant medication use in younger patients with
preserved kidney function would help clinicians identify
population groups that may be able to tolerate this
combination of medications. Future studies would also
benefit from following the lead of Antoniou et al and Fralick
et al in designing studies with patient-centered outcomes
rather than laboratory measurements.
